Factors associated with the development of diabetes mellitus in HIV-infected patients on antiretroviral therapy: A case-control study [2]

AIDS

Volumn 17, Issue 6, 2003, Pages 933-935

  Palacios, Rosario ^a   Santos, Jesús ^a   Ruiz, Josefa ^a   González, Mercedes ^a   Márquez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; BODY MASS; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LETTER; LIPODYSTROPHY; MALE; OBESITY; OUTPATIENT; PATIENT SELECTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AGED; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 0037625969     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200304110-00025     Document Type: Letter

References (20)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
2. Dubé MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000, 31:1467-1475.
3. Dever LL, Oruwari PA, Figueroa WE, O'Donovan CA, Eng RH. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Ann Pharmacother 2000, 34:580-584.
4. Carr A, Samaras K, Thrisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
5. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 1998, 12:F167-F173.
6. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13:F63-F70.
7. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000, 23:35-43.
8. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1998, 21 (Suppl.):S5-S19.
9. National Cholesterol Education Program. Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 10:299-313.
10. Bray G, Bouchard C, James WPT (editors). Definitions and proposed current classifications of obesity. In: Handbook of obesity. New York: Marcel Dekker; 1998. pp. 31-40.
11. Hommes MJT, Romijn JA, Endert E, Eeftinck Schattenkerk JKE, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus infected men. Metabolism 1991, 40:651-656.
12. Geffner ME, Yeh DY, Ladaw EM. In vitro insulin-like growth factor-I, growth hormone and insulin resistance occurs in symptomatic human immunodeficiency virus-1-infected children. Pediatr Res 1993, 34:66-72.
13. Shikuma CM, Waslien C, McKeague J, Baker N, Arakaki M, Cui XW, et al. Fasting hyperinsulinemia and increased waist-to-hip ratios in non-wasting individuals with AIDS. AIDS 1999, 13:1359-1365.
14. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus (HIV). In: FDA Public Health Advisory. Washington, DC: US Food and Drug Administration; 1997.
15. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitors. Ann Intern Med 1997, 127:948.
16. Yarasheski K, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999, 21:209-216.
17. Pardini VC, Victoria IM, Rocha SM, Andrade DG, Rocha AM, Pieroni FB, et al. Leptin levels, beta-cell function, and insulin sensitivity in families with congenital and acquired generalized lipoatrophic diabetes. J Clin Endocrinol Metab 1998, 83:503-508.
18. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL. Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 1999, 48:839-847.
19. Savès M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002, 34:1396-1405.
20. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J, et al. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 1999, 25:225-232.